Humanin vs MOTS-c: Mitochondrial-Derived Peptides for Aging and Metabolism

Introduction#

Humanin and MOTS-c are the two best-characterized members of a new class of bioactive molecules called mitochondrial-derived peptides (MDPs) -- small peptides encoded within the mitochondrial genome rather than nuclear DNA. Both were discovered relatively recently (humanin in 2001, MOTS-c in 2015), and both decline with age, suggesting roles in the aging process. However, they operate through fundamentally different mechanisms and target different aspects of cellular biology.

Humanin is primarily a cytoprotective peptide that prevents programmed cell death (apoptosis) through JAK/STAT signaling and direct interaction with pro-apoptotic proteins. MOTS-c is primarily a metabolic regulator that activates AMPK and enhances insulin sensitivity, functioning as an endogenous exercise mimetic. Together, they represent two arms of mitochondrial communication with the rest of the cell and the organism.

Mechanism of Action Comparison#

Humanin#

Humanin (HN) is a 24-amino acid peptide encoded by the MT-RNR2 gene within mitochondrial 16S rRNA. It was first identified in a screen for factors that protect neurons from amyloid-beta toxicity in Alzheimer disease. Its mechanisms include:

• Anti-apoptotic signaling: Humanin binds directly to Bax and IGFBP-3, two pro-apoptotic proteins, preventing their activation and subsequent mitochondrial membrane permeabilization
• JAK2/STAT3 pathway: Humanin activates a trimeric receptor complex (CNTFR/WSX-1/gp130), which signals through JAK2, leading to STAT3 phosphorylation and nuclear translocation to regulate cytoprotective gene expression
• MAPK activation: Also engages ERK1/2 and p38 MAPK pathways for cell survival signaling
• Oxidative stress reduction: Reduces intracellular reactive oxygen species (ROS) and reactive nitrogen species (RNS)

A potent synthetic analog, HNG (S14G-humanin), has approximately 1000-fold greater neuroprotective activity than native humanin and is commonly used in preclinical research.

MOTS-c#

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded by the MT-RNR1 gene within mitochondrial 12S rRNA. It was discovered by Pinchas Cohen's group at the University of Southern California. Its mechanisms include:

• AMPK activation: MOTS-c activates AMPK through the folate-AICAR-AMPK pathway, inhibiting the folate cycle and leading to accumulation of AICAR, a potent endogenous AMPK activator
• Insulin sensitization: Enhances insulin signaling in skeletal muscle and liver, improving glucose uptake and utilization
• Mitochondrial biogenesis: Promotes the creation of new mitochondria, increasing cellular energy production capacity
• Nuclear translocation: Under metabolic stress, MOTS-c translocates to the nucleus where it regulates gene expression related to antioxidant defense and metabolic homeostasis
• Exercise response: Skeletal muscle MOTS-c levels increase 11.9-fold during acute exercise in humans, with circulating levels rising approximately 1.6-fold

Mechanistic Comparison#

Dosing Comparison#

Humanin Dosing#

No standardized human dosing exists. Preclinical research has used:

• HNG analog (S14G-humanin): 0.1-10 mg/kg in animal studies, typically intraperitoneal
• Native humanin: Circulating levels in humans are approximately 0.5-2 ng/mL, declining with age
• Route: Subcutaneous or intraperitoneal in animal models; crosses the blood-brain barrier
• Duration: Typically acute or short-course administration in preclinical studies

MOTS-c Dosing#

No established human dosing protocols. Research contexts include:

• Animal studies: 5-15 mg/kg intraperitoneal injection in mice
• Circulating levels: Approximately 125 pg/mL at rest in humans, rising to ~190 pg/mL with exercise
• Route: Intraperitoneal in animal studies; subcutaneous in research settings
• Duration: Daily administration in metabolic studies; single doses in exercise studies

Side Effects Comparison#

Humanin Side Effects#

No human interventional safety data exists. Based on preclinical research:

• Preclinical tolerance: Generally well tolerated in animal studies with no reported dose-limiting toxicities
• Endogenous peptide: As a naturally occurring molecule, expected to have favorable safety
• Theoretical concerns: Excessive anti-apoptotic signaling could theoretically interfere with normal programmed cell death (including cancer surveillance), though this has not been observed
• GH/IGF-1 interaction: Humanin levels are inversely regulated by GH/IGF-1 signaling, which may have implications for hormonal balance

MOTS-c Side Effects#

No substantial human safety data exists. Based on available research:

• Preclinical tolerance: Well tolerated in animal metabolic studies
• WADA status: Prohibited by the World Anti-Doping Agency, indicating recognized biological activity
• Endogenous peptide: Naturally produced, particularly during exercise, suggesting physiological safety
• Theoretical concerns: Chronic AMPK activation could theoretically affect fertility or bone metabolism, though not observed in preclinical studies
• Long-term effects: Unknown consequences of chronically elevating MOTS-c beyond physiological levels

Research Evidence Comparison#

Humanin Research#

• Neuroprotection: Original discovery showed protection against amyloid-beta-induced neuronal death. Subsequent studies confirmed protection in Alzheimer disease models, cerebral ischemia, and prion disease models
• Cardiovascular: HNG (S14G-humanin) reduced infarct size in myocardial ischemia-reperfusion models and showed anti-atherogenic properties
• Diabetes: Improved insulin sensitivity and reduced pancreatic beta-cell apoptosis in diabetic mouse models
• Longevity association: Higher circulating humanin levels correlated with longer lifespan in human cohort studies. Centenarians and their offspring tend to have higher humanin levels
• GH/IGF-1 axis: Humanin is negatively regulated by growth hormone, potentially linking it to the longevity benefits of reduced GH signaling

Evidence level: Low -- extensive preclinical data and observational human correlations, but no human interventional trials.

MOTS-c Research#

• Metabolic syndrome: Reversed diet-induced obesity and insulin resistance in mice without changes in food intake or physical activity
• Exercise physiology: Demonstrated 11.9-fold increase in skeletal muscle MOTS-c during acute exercise in healthy young men, establishing it as an exercise-responsive factor
• Aging: MOTS-c levels decline with age in both mice and humans. Exogenous MOTS-c improved physical performance in aged mice
• Diabetes models: Enhanced skeletal muscle glucose uptake and improved insulin signaling in diabetic animal models
• Mitochondrial function: Restored mitochondrial respiration in type 2 diabetic heart models

Evidence level: Low -- strong preclinical data with some human observational/biomarker studies, but very limited human interventional data.

Key Differences Summary#

• Primary function: Humanin protects cells from death (anti-apoptotic). MOTS-c regulates energy metabolism (exercise mimetic).
• Signaling pathway: Humanin signals through JAK2/STAT3 and Bax inhibition. MOTS-c signals through AMPK activation.
• Therapeutic niche: Humanin for neurodegeneration and cellular stress. MOTS-c for metabolic disease and physical performance.
• Exercise connection: MOTS-c is strongly exercise-responsive (11.9-fold muscle increase). Humanin's relationship to exercise is less characterized.
• Longevity link: Humanin has stronger human correlational data linking levels to lifespan. MOTS-c has stronger preclinical interventional data for healthspan.
• Discovery timeline: Humanin (2001) has a longer research history. MOTS-c (2015) is more recently discovered with a rapidly growing literature.
• Clinical development: Neither has advanced to formal clinical trials, though both are subjects of active research.

Conclusion#

Humanin and MOTS-c represent two distinct arms of mitochondrial-derived peptide biology. Humanin excels in cytoprotection -- keeping cells alive under stress -- with its strongest data in neuroprotection and cardiovascular protection. MOTS-c excels in metabolic regulation -- optimizing energy use -- with its strongest data in insulin sensitization and exercise mimicry.

Both peptides decline with age, and this decline may contribute to age-related disease. However, they address aging from different angles: humanin by preventing the cellular damage that accumulates with age, and MOTS-c by maintaining the metabolic fitness that declines with age. For longevity research, the two peptides are genuinely complementary rather than competitive, and understanding both is essential for the emerging field of mitochondrial-derived peptide biology.

Neither peptide has sufficient human interventional data to recommend for clinical use. Both remain primarily research tools, though the scientific rationale for both is strong and growing.

Further Reading#

• Humanin Overview and Research Guide
• Humanin Side Effects
• Humanin Dosing Protocols
• MOTS-c Overview and Research Guide
• MOTS-c Side Effects
• MOTS-c Dosing Protocols